CTLA4 and neoplasm: At the conclusion of that work, we hypothesized that controlled regional delivery of low-dose anti-CTLA-4 results in a sustained perfusion of tumor draining lymph nodes (TDLN) that selectively expands and activates tumor-specific T cells while sparing autoimmune T cell activation at distant nodal sites.